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Erythropoietin Receptor Signaling Mitigates
Renal Dysfunction-Associated Heart Failure
by Mechanisms Unrelated to Relief of Anemia
Atsushi Ogino, MD,* Genzou Takemura, MD,* Masanori Kawasaki, MD,* Akiko Tsujimoto, BS,*
Hiromitsu Kanamori, MD,* Longhu Li, MD,* Kazuko Goto, PHD,* Rumi Maruyama, PHD,*
Itta Kawamura, MD,* Toshiaki Takeyama, MD,* Tomonori Kawaguchi, MD,*
Takatomo Watanabe, MD,* Yoshiyuki Moriguchi, MS,† Hideki Saito, MS,† Takako Fujiwara, MD,‡
Hisayoshi Fujiwara, MD,§ Shinya Minatoguchi, MD*
Gifu, Shizuoka, Kyoto, and Hyogo, Japan
Objectives We examined the effect of asialoerythropoietin (asialoEPO), a nonerythrogenic derivative of erythropoietin (EPO),
on renal dysfunction-associated heart failure.
Background Although EPO is known to exert beneficial effects on cardiac function, the clinical benefits in patients with
chronic kidney disease are controversial. It remains to be addressed whether previously reported outcomes were
the result of relief of the anemia, adverse effects of EPO, or direct cardiovascular effects.
Methods Mice underwent 5/6 nephrectomy to cause renal dysfunction. Eight weeks later, when renal dysfunction was
established, anemia and cardiac dysfunction and remodeling were apparent. Mice were then assigned to receive
saline (control), recombinant human erythropoietin (rhEPO) at 5,000 IU (714 pmol)/kg, or asialoEPO at 714
pmol/kg, twice/week for 4 weeks.
Results Although only rhEPO relieved the nephrectomy-induced anemia, both rhEPO and asialoEPO significantly and sim-
ilarly mitigated left ventricular dilation and dysfunction. The hearts of rhEPO- or asialoEPO-treated mice showed
less hypertrophy, reflecting decreases in cardiomyocyte hypertrophy and degenerative subcellular changes, as
well as significant attenuation of fibrosis, leukocyte infiltration, and oxidative deoxyribonucleic acid damage.
These phenotypes were accompanied by restored expression of GATA-4, sarcomeric proteins, and vascular endo-
thelial growth factor and decreased inflammatory cytokines and lipid peroxidation. Finally, myocardial activation
was observed of extracellular signal-regulated protein kinase and signal transducer and activator of transcription
pathways in the treated mice.
Conclusions EPO receptor signaling exerts direct cardioprotection in an animal model of renal dysfunction-associated heart
failure, probably by mitigating degenerative, pro-fibrosis, inflammatory, and oxidative processes but not through
relief of anemia. (J Am Coll Cardiol 2010;56:1949–58) © 2010 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.04.068s
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mrythropoietin (EPO) is a hypoxia-induced hormone that is
ssential for normal erythropoiesis and has been used
roadly in patients with anemia. Notably, however, expres-
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010, accepted April 27, 2010.ion of the EPO receptor within the cardiovascular system,
ncluding on cardiomyocytes and endothelial cells, suggests
PO exerts cardiovascular effects beyond hematopoiesis
1–3). For instance, recombinant human erythropoietin
rhEPO) exerts cardioprotective effects in hearts subjected
See page 1959
o acute myocardial infarction or ischemia-reperfusion in-
ury (i.e., EPO administration either before or during
yocardial ischemia significantly enhances functional re-
overy after reperfusion) (4,5). In addition, EPO adminis-
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of myocardial infarction miti-
gates the cardiac dysfunction and
remodeling caused by old myo-
cardial infarctions through dif-
ferent mechanisms (6). A pro-
tective effect of EPO was also
demonstrated against heart disease
having a nonischemic origin (e.g.,
doxorubicin cardiomyopathy) (7).
These findings suggest that EPO
acts as a tissue-protective cytokine
in heart disease and that it exerts
different effects on diseased hearts
through various mechanisms, de-
pending on the disease type.
Cardiovascular complications
are an important clinical problem
in patients with chronic kidney
disease (CKD), accounting for
up to 40% of deaths among pa-
tients with end-stage disease (8).
Ischemic heart disease, heart fail-
ure, and cardiomyopathy are the
most frequent causes of death,
and cross-sectional studies have
shown that left ventricular (LV)
hypertrophy, which is an inde-
pendent risk factor for survival
9), is the most frequent cardiac alteration in CKD. The
ncidence of anemia is also increased among patients with
KD (10), and correction of the anemia with EPO report-
dly improves cardiac function in patients with CKD-
ssociated heart failure (11,12). However, more recent
linical trials challenged the benefits of improving anemia
ith EPO in CKD patients and reported no benefits and
ome adverse outcomes (13–15). In any case, however, it is
ifficult to determine the underlying mechanisms because of
he multiple actions of EPO (i.e., a direct protective effect
n the cardiovascular system, erythropoiesis that improves
issue hypoxia but also causes polycythemia, possible acti-
ation of the rennin-angiotensin and endothelin systems
ith resultant hypertension) (16–20). Furthermore, correc-
ion of anemia could lead to harm, if anemia is a compen-
atory mechanism in patients with CKD.
We hypothesized that relief of anemia might not be
equired for the beneficial effect of EPO on the CKD-
ssociated cardiac dysfunction. As a means of testing that
dea, asialoEPO, a nonerythropoietic variant of EPO, at-
racted our attention (21,22). Because asialoEPO is derived
rom EPO by removing all of the sialic acids, which delay its
learance in vivo, asialoEPO is too short-lived to mediate
rythropoiesis, which requires the continuous presence of
PO. In rats, intravenously injected asialoEPO has a
redominant plasma half-life of 1.4 min, which is well-
Abbreviations
and Acronyms
4-HNE  4-hydroxyl-2-
nonenal
8-OHdG  8-hydroxy-2’-
deoxyguanosine
Akt  protein kinase B
CKD  chronic kidney
disease
ELISA  enzyme-linked
immunosorbent assay
EPO  erythropoietin
ERK  extracellular signal-
regulated protein kinase
LV  left ventricle/
ventricular
MCP  monocyte
chemoattractant protein
MHC  myosin heavy chain
rhEPO  recombinant
erythropoietin
STAT  signal transducer
and activator of
transcription
TUNEL  terminal dUTP
nick-end labeling
VEGF  vascular
endothelial growth factorelow the lower limit for quantification in the systemic tirculation within 1 to 2 h. By contrast, the plasma half-life
f rhEPO is 5.6 h (22). Administration of asialoEPO via
ntraperitoneal or subcutaneous routes gives rise to effective
lasma half-lives of 0.5 and 2.5 h, respectively (22). In the
resent study, we evaluated the effects of asialoEPO in
omparison with rhEPO in a murine model of heart failure
nduced by 5/6 nephrectomy and investigated the specific
echanisms and molecular signals involved in their effects.
ethods
hEPO and asialoEPO. The rhEPO was purchased from
hugai Pharmaceutical Company, Ltd. (Tokyo, Japan).
sialoEPO was prepared from rhEPO as previously de-
cribed (21).
nimal model and experimental protocol. This study was
pproved by our Institutional Animal Research Committee.
he 5/6 kidney ablation was performed in 50 male
57BL/6J mice at the age of 10 weeks (CLEA, Tokyo,
apan) (23). This entailed initial removal of both poles of
he right kidney followed by removal of the entire left
idney 1 week later. At 8 weeks after the second operation,
0 mice remained alive, and they were divided into 3
roups: a saline-treated (control) group (n  10); an
hEPO-treated group (5,000 IU/kg  714 pmol/kg  25
g/kg, subcutaneous injection twice/week for 4 weeks, n 
0); and an asialoEPO-treated group (714 pmol/kg  23
g/kg, subcutaneous injection twice/week for 4 weeks, n 
0). The dose of rhEPO was within a narrow range of doses
nown to mediate organ protection (5–8); the same dose of
sialoEPO was given. Mice were also subjected to sham
perations in which the mice were operated on, but kidney
blation was not carried out. In those mice, administration
f saline, rhEPO, or asialoEPO (n  6 each) was started 8
eeks after the operation and continued for 4 weeks. The
nimals were then examined by investigators blinded to the
ssigned animal group.
lood sampling. Blood samples were collected at ap-
roximately 5:00 PM from the tail vein before nephrec-
omy, before starting treatment (8 weeks later), and at the
nd of the experiment (12 weeks later). The samples were
ssayed for serum creatinine, blood urea nitrogen, and
emoglobin with standardized methods (i.e., the enzyme
ethod, the urease-LEDH method, and the SLS-Hb
ethod, respectively).
hysiology studies. Physiological studies (echocardiogra-
hy and cardiac catheterization) were carried out under
nesthesia with halothane (induction, 2%; maintenance,
.5%) in a mixture of nitrous oxide and oxygen (0.5 l/min
ach) via a nasal mask as described previously (23).
istological analysis. Once the physiological measurements
ere complete, all surviving mice were killed, and the hearts
ere removed. The basal specimens were fixed in 10% buffered
ormalin, embedded in paraffin, cut into 4-m-thick sections,
nd stained with hematoxylin-eosin, Masson’s trichrome, and
irius red F3BA (Sigma-Aldrich, St. Louis, Missouri). Quan-
itative assessments, including cardiomyocyte size (expressed as
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November 30, 2010:1949–58 Erythropoietins in CKD-Associated Heart Failurehe transverse diameter of myocytes cut at the level of the
ucleus), cell number, and the area of fibrosis, were carried out
n randomly chosen high-power fields (400) in each section
ith a multipurpose color image processor (LUZEX F, Ni-
eco, Tokyo, Japan).
mmunohistochemistry. The 4-m-thick deparaffinized
ections were incubated with an antibody against Flk-1
Santa Cruz Biotechnology, Santa Cruz, California), pan-
eukocyte antigen (CD45, Pharmingen, San Diego, Cali-
ornia), 8-hydroxy-2=-deoxyguanosine (8-OHdG) (Japan
nstitute of the Control of Aging), myosin heavy chain
MHC) (Santa Cruz) or laminin (Progen, Heidelberg,
ermany). An ABC kit (Dako, Carpinteria, California) was
sed for immunostaining with DAB as the chromogen, and
uclei were counterstained with hematoxylin. When immu-
ostaining laminin in combination with filamentous actin
taining (stained with rhodamine-phalloidin; Molecular
robes, Eugene, Oregon), Alexa Fluor 488 (Molecular
robes) was the secondary antibody, and nuclei were coun-
erstained with Hoechst 33342. The primary antibodies
ere substituted with the respective control immunoglobu-
in G for the control sections.
To evaluate the incidence of apoptosis among cardiomy-
cytes, we immunofluorescently labeled with anti-
yoglobin antibody (DAKO) in combination with in
itu terminal dUTP nick-end labeling (TUNEL) with
luorescein-FragEL (Oncogene, Boston, Massachusetts).
mmunostained preparations were observed under a confo-
al microscope (LSM510, Zeiss, Jena, Germany).
lectron microscopy. Cardiac ultrastructure was examined
y the conventional method as previously described (7)
nder a transmission electron microscope (H-800, Hitachi,
okyo, Japan).
estern blotting. Lysates from heart tissues (n  3 to 5
rom each group) were used for Western blot analysis.
roteins were separated and transferred to membranes with
tandard protocols, after which they were probed with
ntibodies against GATA-4, MHC, troponin I (all from
anta Cruz), vascular endothelial growth factor (VEGF)
Santa Cruz), transforming growth factor-beta-1 (Pro-
ega), cyclooxygenase-2 (Santa Cruz), monocyte chemoat-
ractant protein (MCP)-1 (Santa Cruz), and 4-hydroxyl-2-
onenal (4-HNE) (NOF Corporation, Tokyo, Japan).
ctivation of extracellular signal-regulated protein kinase
ERK), protein kinase B (Akt), signal transducer and
ctivator of transcription-3 (STAT3), and STAT5—all
ownstream mediators of EPO receptor signaling—was
ssessed with antibodies against their phosphorylated forms,
-ERK, p-Akt, p-STAT3, and p-STAT5 (all from Cell
ignaling, Danvers, Massachusetts). The blots were visual-
zed by means of chemiluminescence (Amersham, Uppsala,
weden), and the signals were quantified by densitometry.
he alpha-tubulin (analyzed with an antibody from Santa
ruz) served as the loading control.
nzyme-linked immunosorbent assays (ELISAs). Levels
f interleukin-1-beta, interleukin-6, and tumor necrosis nactor-alpha in the myocardium were assayed with ELISAs
R&D Systems, Minneapolis, Minnesota). Three to five
earts from each group were used for this assay.
tatistical analysis. Values were shown as mean  SEM.
he significance of the differences in variance was evaluated
ith the Bartlett test. When the variance was significantly
ifferent, the significance of differences was tested by the
ruskal-Wallis test. Otherwise, it was evaluated with 1-way
nalysis of variance with a post hoc Newman-Keul’s multi-
le comparison test or a repeated-measures analysis of
ariance (Figs. 1 and 2A). Values of p  0.05 were
onsidered significant.
esults
urvival, renal function, and hemoglobin levels. Two of
he nephrectomized mice died during treatment; both
elonged to the saline-treated group (survival rate, 80%). All
f the mice in the rhEPO- and asialoEPO-treated groups as
ell as the sham-operated mice survived to the end of
xperiment. Measured 8 and 12 weeks after the operation,
erum creatinine and blood urea nitrogen levels were sig-
ificantly higher in all nephrectomized groups than in the
ham-operated groups. Neither rhEPO nor asialoEPO
ffected renal function in any group (Fig. 1). Hemoglobin
evels were significantly diminished 8 weeks after nephrec-
omy. In addition to relieving anemia in the nephrectomized
ice, rhEPO also increased hemoglobin to higher-than-
Figure 1 Renal Function and Anemia
*p  0.05 versus pre-operation; #p  0.05 versus pre-treatment. BUN 
blood urea nitrogen; other abbreviations as in Figure 1.ormal levels (polycythemia) in the sham-operated mice. By
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Erythropoietins in CKD-Associated Heart Failure November 30, 2010:1949–58ontrast, asialoEPO had no effect on the hemoglobin levels
n sham-operated or nephrectomized mice.
ardiac function and remodeling. Echocardiography and
ardiac catheterization revealed an enlarged LV cavity and
mpaired LV function in nephrectomized mice 8 weeks after
he operation: LV end-diastolic diameter was increased, and
V ejection fraction was reduced, as compared with sham-
perated mice (Fig. 2A). This LV dilation and dysfunction
orsened during the subsequent 4 weeks in the saline-
reated mice. By contrast, mice treated with rhEPO or
sialoEPO exhibited a smaller LV cavity and improved LV
unction after treatment, as compared with the saline-
reated nephrectomized mice (Fig. 2A). Cardiac catheter-
zation confirmed improvement of LV systolic and diastolic
unction as assessed by dP/dt in nephrectomized mice
reated with either rhEPO or asialoEPO (Fig. 2B). The
ephrectomized mice showed lower blood pressure with no
Figure 2 Cardiac Function and Geometry
Assessed by echocardiography (A) and cardiac catheterization (B). *p  0.05 ver
treated nephrectomized group. Baseline values were not shown, because neither echo
asialoerythropoietin; EPO  erhthropoietin; rhEPO  recombinant human erythropo
diameter (mm); LVEDP  left ventricular end-diastolic pressure (mm Hg); SBP  pignificant difference from the sham, which tended to be oigher with rhEPO and was significantly increased with
sialoEPO (Fig. 2B).
istological and immunohistochemical findings in the
eart. The heart weight and heart weight/body weight
atios in nephrectomized mice were greater than those in
ham groups, which were accompanied by cardiomyocyte
ypertrophy (Table 1, Figs. 3A and 3B). In addition,
lectron microscopy revealed significant degeneration in the
ypertrophied cardiomyocytes from nephrectomized mice
n the saline group. These included myofibrillar disorgani-
ation and loss and accumulation of mitochondria showing
eformities, swelling, and/or degeneration. Such were sig-
ificantly attenuated by rhEPO and asialoEPO (Fig. 4A).
y contrast, we failed to find ultrastructure indicative of
poptosis among cardiomyocytes in any group.
Sirius red staining showed significantly greater myocar-
ial fibrosis in the nephrectomized mice than in the sham-
am-operated group with the corresponding treatment; #p  0.05 versus saline-
graphy nor cardiac catheterization was performed before nephrectomy. asialoEPO 
EF  (left ventricular) ejection fraction (%); LVDd  left ventricular end-diastolic
stolic blood pressure (mm Hg); Tx  treatment.sus sh
cardio
ietin.
eak syperated mice (Fig. 3C, Table 1). Capillary density, which
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November 30, 2010:1949–58 Erythropoietins in CKD-Associated Heart Failureas evaluated in terms of the myocardial Flk-1-positive cell
ount, was significantly smaller in nephrectomized mice
Fig. 3D), as was the capillaries/cardiomyocytes ratio
Table 1). In addition, infiltration of CD45-positive leukocytes
nto the myocardium was significantly greater in nephrecto-
ized mice (Fig. 3E, Table 1). The modified deoxyribonu-
leic acid base 8-OHdG is a commonly used marker of
xidative damage to deoxyribonucleic acid (24), and the
ncidence of 8-OHdG–positive cardiomyocytes was also
arkedly greater in nephrectomized mice (Fig. 3F, Table 1).
ll these detrimental nephrectomy-induced phenotypes in
he myocardium were significantly attenuated by treatment
ith rhEPO or asialoEPO. The TUNEL-positivity was
xtremely rare among cardiomyocytes in all the groups, and
here was no significant difference in its prevalence among
he groups (Table 1).
In summary, nephrectomy caused cardiac hypertrophy,
ardiomyocyte hypertrophy with degenerative subcellular
hanges, increases in fibrosis, reductions in capillary density,
nd increases in leukocyte infiltration and oxidative damage
n the heart. Treatment with rhEPO or asialoEPO miti-
ated all of them, and there was little or no difference
etween the effects of the 2 compounds.
xpression of sarcomeric proteins and GATA-4. Because
ephrectomy caused cardiomyocyte hypertrophy with
bvious myofibrillar loss, we examined the expression of
sarcomeric proteins, MHC and troponin I, as well as
ATA-4 —a key transcription factor regulating expres-
ion of sarcomeric proteins in the heart, including MHC
nd troponin I (25,26). Myocardial levels of GATA-4
ere found to be significantly reduced in nephrectomized
ice (Fig. 4B), as were levels of MHC and troponin I.
he inhibitory effect of nephrectomy on the expression of
ll 3 proteins was significantly reversed by rhEPO or
sialoEPO (Fig. 4B).
nflammatory and angiogenic mediators and lipid
eroxidation. Nephrectomy was found to evoke inflam-
atory responses and oxidative damage in the heart.
eart Weights, HW/BW Ratios, and Histological Morphometry of tTable 1 Heart Weights, HW/BW Ratios, and Histological Morp
Sham
Saline
(n  6)
rhEPO
(n  6)
Heart weight, mg 98 2 98 4
HW/BW, mg/g 3.62 0.07 3.55 0.12
Myocyte size, m 12.7 0.4 12.6 0.3
% Fibrosis 0.77 0.12 0.58 0.05
CD45 leukocytes/HPF 2.1 0.1 2.0 0.1
8-OHdG cells, % 1.96 0.17 1.82 0.38
Flk-1 vessels/HPF 366 6 358 9
Vessel/myocyte ratio 0.67 0.01 0.64 0.02
TUNEL myocytes, % 0.031 0.009 0.032 0.008 0
p  0.05 versus the saline-treated sham-operated group; †p  0.05 versus the saline-treated ne
8-OHdG  8-hydroxy-2’-deoxyguanosine; AsialoEPO  asialoerythropoietin; HW/BW  heart w
UNEL  terminal dUTP nick-end labeling.mong the inflammatory mediators assayed with LLISAs or Western blotting, expression of interleukin-
–beta and interleukin-6 and MCP-1 but not tumor necrosis
actor-alpha, transforming growth factor–beta-1, or cyclo-
xygenase-2 was induced after nephrectomy (Fig. 5). This
verexpression was largely reversed by treatment with rhEPO
r asialoEPO. Myocardial expression of VEGF was signifi-
antly down-regulated by nephrectomy, but it was greatly
ugmented when treated with rhEPO or asialoEPO (Fig. 5).
estern blotting of 4-HNE, a marker of oxidative damage to
ell membranes (27), indicated that nephrectomy increased
ipid peroxidation in the heart, but treatment with rhEPO
r asialoEPO significantly reduced the 4-HNE level (Fig. 5).
ctivation of downstream mediators of EPO receptor.
xtracellular signal-regulated protein kinase, phosphatidyl-
nositol 3-kinase/Akt and receptor-associated Janus family
yrosine kinase/STAT are known to be downstream medi-
tors of EPO receptor signaling in cardiac cells, both in
itro and in vivo (4,7). Phosphorylation (activation) of ERK
as augmented in hearts from nephrectomized mice, and
his effect was further enhanced by rhEPO or asialoEPO,
hereas Akt activity was unaffected by nephrectomy,
hEPO, or asialoEPO (Fig. 6). Activation of STAT3 and
TAT5 was inhibited in hearts from the nephrectomized
ice, but this was significantly attenuated by rhEPO or
sialoEPO (Fig. 6).
iscussion
e noted significant renal dysfunction and anemia in mice
fter 5/6 nephrectomy. Nephrectomy also induced LV
emodeling (dilation) and dysfunction, which were accom-
anied by cardiomyocyte hypertrophy with degenerative
ubcellular changes, myocardial interstitial fibrosis, reduc-
ions in capillary density, leukocyte infiltration, and oxida-
ive damage. The rhEPO but not asialoEPO exerted an
rythrogenic effect that relieved the anemia, but neither
ffected renal function in this model. That these 2
ompounds similarly attenuated nephrectomy-induced
arttry of the Heart
Nephrectomy
loEPO
6)
Saline
(n  8)
rhEPO
(n  10)
AsialoEPO
(n  10)
4 130 6* 96 6† 116 4*†
0.14 4.98 0.20* 3.63 0.21† 4.08 0.13*†
0.1 15.2 0.5* 13.3 0.7† 13.5 0.3†
0.08 4.51 0.23* 2.59 0.13*† 3.18 0.33*†
0.2 4.9 0.2* 3.3 0.2*† 3.2 0.1*†
0.28 8.25 1.25* 5.29 0.24*† 6.75 0.73*†
9 321 11* 378 9† 372 7†
0.02 0.60 0.01* 0.69 0.02† 0.69 0.01†
0.011 0.042 0.009 0.041 0.006 0.041 0.006
omy group.
ody weight ratio; HPF  high power field (400); rhEPO  recombinant human erythropoietin;he Hehome
Asia
(n 
97
3.59
12.6
0.82
2.0
1.89
356
0.64
.032
phrectV remodeling and dysfunction indicates that EPO
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Erythropoietins in CKD-Associated Heart Failure November 30, 2010:1949–58eceptor signaling protects the hearts of mice with renal
ysfunction through mechanisms unrelated to erythro-
enesis. The neuroprotective action of EPO receptor
ignaling is well known (21,22). One feature that distin-
uishes erythropoiesis from neuroprotection is that effec-
ive production of erythrocytes requires continuous stim-
lation of EPO receptors, whereas a brief stimulation is
ufficient for neuroprotection (21). This might also hold
rue for cardioprotection. A recent study actually reported
cardioprotective effect of a low-dose EPO that causes
o erythropoiesis in a post-infarction heart failure model
28), also suggesting that EPO receptor signaling might
ave a role in heart failure in general and not just
Sham
+Saline +Saline
A
B
C
D
E
F
F-actin 
+ Laminin
Figure 3 Histology and Immunohistochemistry of the Heart
(A) Transverse ventricular section stained with Masson’s trichrome. (B) Cardiomy
(red). (C) Myocardial fibrosis visualized by staining with Sirius red. (D) Capillary de
visualized on the basis of anti-CD45 immunostaining. (F) Oxidative deoxyribonucle
(8-OHdG) immunostaining. Bars  1 mm in A; 20 m in the other panels. Abbrevissociated with CKD. Tossible mechanisms underlying beneficial effects of
PO receptor stimulation. Our findings suggest that
everal factors contribute to the cardioprotective effects of
PO receptor signaling stimulated by rhEPO or asialo-
PO against renal dysfunction-induced heart failure.
he first is that EPO receptor signaling exerts an
ntidegenerative effect on cardiomyocytes. Indeed, LV
ypertrophy is initially an adaptive response to an in-
rease in cardiac work against volume and/or pressure
verload, and we observed both LV hypertrophy and
ardiomyocyte hypertrophy (increase in cell diameter)
fter nephrectomy. Although apoptosis among cardiomy-
cytes might be an aggravating factor in heart failure, our
Nephrectomy
       +rhEPO             +AsialoEPO
egeneration visualized by immunostaining laminin (green) and filamentous actin
visualized by immunostaining with anti-Flk-1. (E) Leukocyte infiltration (arrows)
damage (arrows) visualized on the basis of anti-8-hydroxy-2’-deoxyguanosine
as in Figure 1.       
ocyte d
nsity
ic acid
ationsUNEL assays and electron microscopic findings suggest
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November 30, 2010:1949–58 Erythropoietins in CKD-Associated Heart Failureardiomyocyte apoptosis is not important in the present
odel. Instead, affected cardiomyocytes show severe
egenerative changes, including myofibrillar derange-
ent, disruption, and loss, as well as proliferation of
ubcellular organelles such as mitochondria. Because
ATA-4 is a key transcription factor regulating expres-
ion of cardiac sarcomeric proteins (e.g., MHC and
roponin I) (25,26), it seems plausible that its down-
egulation underlies the observed sarcomeric disintegra-
ion. We confirmed that, consistent with that idea, there
s a significant reduction in cardiac GATA-4 levels after
ephrectomy, but we also noted that this reduction could
e significantly reversed by EPO receptor stimulation and
hat expression of MHC and troponin I varied in
ccordance with the GATA-4 level. We previously re-
orted that rhEPO could restore GATA-4 expression in
Figure 4 Cardiomyocyte Degeneration
(A) Representative electron micrographs of cardiomyocytes from sham-oper-
ated mice (upper left) and nephrectomized mice administered saline (upper
right), rhEPO (lower left), or asialoEPO (lower right). Bars  1 m. (B) Western
blots and the densitometries for GATA-4, myosin heavy chain (MHC), and troponin
I. *p  0.05 versus the sham operated group; #p  0.05 versus the nephrecto-
mized group administered saline. Abbreviations as in Figures 1 and 2.ultured cardiomyocytes in which it was down-regulatedy treatment with doxorubicin (7). We suggest that the
eneficial effect of EPO receptor stimulation on GATA-4
xpression, myofibrillar content, and sarcomeric integrity is a
ey element underlying the observed improvement in cardiac
unction in the present model, because these changes would
irectly influence the contractile power of individual
ardiomyocytes.
In addition to cardiomyocyte hypertrophy, increased
yocardial fibrosis and reduced myocardial capillary density
ave been shown to play significant roles in cardiac remod-
ling in humans with end stage renal disease (29). We observed
n our nephrectomized mouse model that renal dysfunction
eads to myocardial fibrosis; myocardial inflammation with
eukocyte infiltration; overexpression of inflammatory cyto-
ines, including interleukin-1-beta, interleukin-6, and
CP-1; reduced capillary density; and oxidative damage. A
Figure 5 Levels of Inflammatory and Angiogenic
Mediators and Lipid Peroxidation in the Heart
(A) Myocardial levels of interleukin (IL)-1-beta and IL-6 and tumor necrosis fac-
tor-alpha (TNF-alpha) (pg/mg protein) determined by enzyme-linked immunosor-
bent assay. (B) Western blotting of vascular endothelial growth factor (VEGF),
transforming growth factor (TGF)-beta-1, cyclooxygenase 2 (COX-2), monocyte
chemoattractant protein (MCP)-1, and 4-hydroxyl-2-nonenal (4-HNE). *p  0.05
versus the sham-operated group; #p  0.05 versus the nephrectomized group
administered saline. Abbreviations as in Figures 1 and 2.
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ccompanies reactive interstitial fibrosis in the setting of
eart failure (30). Angiogenic activity of rhEPO was
lready reported in post-infarction heart failure (31), and
very recent study reported that induction of VEGF
hrough the STAT3 pathway is the molecular mechanism
Figure 6 Western Blot Analysis
Western blot analysis of the downstream mediators of EPO receptor (extracellu-
lar signal-regulated protein kinase [ERK], protein kinase B [Akt], signal trans-
ducer and activator of transcription [STAT]3, and STAT5). *p  0.05 versus
the sham-operated group; #p  0.05 versus the nephrectomized group admin-
istered saline. Abbreviations as in Figures 1 and 2.or EPO-induced angiogenesis (32). In the present study, he confirmed angiogenic activity, restored expression of
EGF, and STAT3 activation in renal dysfunction-
ssociated heart failure and also found that asialoEPO
as the same effects.
Oxidative stress and inflammatory reactions can be crit-
cally associated in a vicious cycle in which they induce and
xacerbate one another. Consequently, in addition to the
tructural maladaptation (e.g., accumulation of collagen in
he cardiac interstitium) that occurs in heart failure and can
ead to LV diastolic dysfunction (30), induction of powerful
nflammatory mediators is also reportedly associated with
eart failure (33,34). These are thought to contribute to the
evelopment and aggravation of renal dysfunction-
ssociated heart failure.
tudy limitations. Kennedy et al. (35) reported that the
/6 nephrectomized mice, a model similar to ours, were
ypertensive when measured by the tail-cuff method with-
ut anesthesia during follow-up for 8 weeks. In contrast, our
ephrectomized mice showed no hypertension. We evalu-
ted blood pressure with cardiac catheterization under
nesthesia in the mice at 12 weeks after nephrectomy when
ardiac pump failure more severely developed. Such differ-
nces might have a strong bearing on the effect of nephrec-
omy on blood pressure in those studies. In addition,
hEPO is known to induce hypertension, which was not
pparent in this study, however. The reason is unclear, but
t might be possible that the dose of rhEPO used here was
ot enough to influence blood pressure in the present mouse
odel.
The treatment with rhEPO or asialoEPO provided
ntidegeneration in cardiomyocytes, reduction in leukocyte
nfiltration, restoration of capillary vessels, and reduction in
brosis in the heart, indicating that the treatment as well as
ephrectomy affected various cell types in the heart. In the
resent study, however, it is difficult to determine which cell
ype or which action on the cells is most responsible for the
eneficial effects of rhEPO and asialoEPO.
This study was not designed or powered to detect
ifferences between the effects of rhEPO and asialoEPO.
lthough the dose used was the same in the present study,
t is not clear whether the dose was even comparable because
f the pharmacokinetic difference between them. Future
tudies are needed to explore the differences.
linical implications. Recent clinical studies raised the
erious question on the beneficial effect of improving anemia
ith EPO on death and cardiovascular/renal events (13–15).
rythropoietin exerts erythropoiesis that indeed improves
ystemic hypoxia but also causes polycythemia, increases in
latelet aggregability, and possible activation of the rennin-
ngiotensin and endothelin systems with resultant hyper-
ension, whereas it has direct protective effects on the
ardiovascular system. Thus, it was difficult to determine the
nderlying mechanisms that explain the clinical outcomes.
he present study has shown that EPO receptor signaling
xerts a protective effect against renal dysfunction-associated
eart failure by mechanisms unrelated to relief of anemia.
T
o
t
a
C
o
b
p
t
c
c
t
c
b
b
s
A
T
(
T
a
R
D
M
g
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
1957JACC Vol. 56, No. 23, 2010 Ogino et al.
November 30, 2010:1949–58 Erythropoietins in CKD-Associated Heart Failurehat is, we ruled out the benefits of anemia improving effect
f EPO in this disease condition. Our findings thus imply
hat a short-lived, nonerythrogenic EPO derivative could be
useful therapeutic agent for heart failure in patients with
KD.
Carbamylated EPO (another nonerythrogenic derivative
f EPO) and certain EPO mutants were reported to not
ind to the classical EPO receptor and show no hemato-
oietic activity (36). Nevertheless, they confer neuroprotec-
ion in models of various neurological disorders (36) and
ardioprotection in ischemia-reperfusion injury and myo-
ardial infarction (37,38). AsialoEPO occurs naturally in
he blood as a metabolite of EPO—assuring safety in its
linical use because it is unlikely to acquire antigenicity—
ut stimulates the classical EPO receptor to evoke not only
eneficial but also harmful effects. Those EPO derivatives
hould be seriously considered for clinical use.
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